CN116355080A - Rsv特异性抗体及其功能部分 - Google Patents

Rsv特异性抗体及其功能部分 Download PDF

Info

Publication number
CN116355080A
CN116355080A CN202211184987.8A CN202211184987A CN116355080A CN 116355080 A CN116355080 A CN 116355080A CN 202211184987 A CN202211184987 A CN 202211184987A CN 116355080 A CN116355080 A CN 116355080A
Authority
CN
China
Prior art keywords
antibody
seq
chain variable
sequence
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211184987.8A
Other languages
English (en)
Chinese (zh)
Inventor
N·厄布兰德
N·凯乐瓦德-勒雷
A·Q·袁
B·里齐特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CN116355080A publication Critical patent/CN116355080A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202211184987.8A 2014-01-15 2015-01-14 Rsv特异性抗体及其功能部分 Pending CN116355080A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15
US61/927,819 2014-01-15
PCT/US2015/011391 WO2015108967A2 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof
CN201580003410.4A CN105916520A (zh) 2014-01-15 2015-01-14 Rsv特异性抗体及其功能部分

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580003410.4A Division CN105916520A (zh) 2014-01-15 2015-01-14 Rsv特异性抗体及其功能部分

Publications (1)

Publication Number Publication Date
CN116355080A true CN116355080A (zh) 2023-06-30

Family

ID=53543612

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211184987.8A Pending CN116355080A (zh) 2014-01-15 2015-01-14 Rsv特异性抗体及其功能部分
CN201580003410.4A Pending CN105916520A (zh) 2014-01-15 2015-01-14 Rsv特异性抗体及其功能部分

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580003410.4A Pending CN105916520A (zh) 2014-01-15 2015-01-14 Rsv特异性抗体及其功能部分

Country Status (26)

Country Link
US (6) US20160340414A1 (https=)
EP (3) EP3741390A1 (https=)
JP (4) JP6836398B2 (https=)
KR (1) KR102188437B1 (https=)
CN (2) CN116355080A (https=)
AU (4) AU2015206570A1 (https=)
CA (1) CA2933200C (https=)
CY (2) CY1123425T1 (https=)
DK (1) DK3094353T3 (https=)
ES (1) ES2795727T3 (https=)
FI (1) FIC20230016I1 (https=)
FR (1) FR23C1016I1 (https=)
HR (1) HRP20200607T1 (https=)
HU (2) HUE048855T2 (https=)
LT (2) LT3094353T (https=)
LU (1) LUC00305I2 (https=)
MX (1) MX374517B (https=)
NL (1) NL301228I2 (https=)
NO (1) NO2023016I1 (https=)
PL (1) PL3094353T3 (https=)
PT (1) PT3094353T (https=)
RS (1) RS60387B1 (https=)
SI (1) SI3094353T1 (https=)
SM (1) SMT202000282T1 (https=)
TW (1) TWI705974B (https=)
WO (1) WO2015108967A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
ES2795727T3 (es) 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20200140799A (ko) * 2018-01-31 2020-12-16 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
CA3229901A1 (en) 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778866A (zh) * 2007-06-01 2010-07-14 米迪缪尼有限公司 Rsv特异性结合分子和产生它们的方法
CN102656189A (zh) * 2009-08-13 2012-09-05 克鲁塞尔荷兰公司 针对人呼吸道合胞病毒(rsv)的抗体以及使用方法
CN103097412A (zh) * 2010-07-09 2013-05-08 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
JP2010534057A (ja) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
US9273118B2 (en) * 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2486053B1 (en) * 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
CA2867444C (en) * 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
US20150158942A1 (en) * 2012-05-22 2015-06-11 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma
CA2900110A1 (en) 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
ES2795727T3 (es) * 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778866A (zh) * 2007-06-01 2010-07-14 米迪缪尼有限公司 Rsv特异性结合分子和产生它们的方法
CN102656189A (zh) * 2009-08-13 2012-09-05 克鲁塞尔荷兰公司 针对人呼吸道合胞病毒(rsv)的抗体以及使用方法
CN103097412A (zh) * 2010-07-09 2013-05-08 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法

Also Published As

Publication number Publication date
EP3094353A4 (en) 2017-09-06
NO2023016I1 (no) 2023-04-25
CY2023011I1 (el) 2023-11-15
JP2025063143A (ja) 2025-04-15
US11661449B2 (en) 2023-05-30
US12173050B2 (en) 2024-12-24
ES2795727T3 (es) 2020-11-24
MX374517B (es) 2025-03-06
US20220098285A1 (en) 2022-03-31
PT3094353T (pt) 2020-06-08
WO2015108967A3 (en) 2015-09-03
CA2933200A1 (en) 2015-07-23
US20250179153A1 (en) 2025-06-05
FR23C1016I1 (fr) 2023-06-23
AU2015206570A1 (en) 2016-07-14
HK1225992A1 (en) 2017-09-22
US20160340414A1 (en) 2016-11-24
TWI705974B (zh) 2020-10-01
AU2021204339B2 (en) 2024-11-14
LUC00305I2 (https=) 2025-09-22
CY2023011I2 (el) 2023-11-15
EP3094353A2 (en) 2016-11-23
AU2020203831A1 (en) 2020-07-02
CA2933200C (en) 2025-05-06
EP3741390A1 (en) 2020-11-25
CY1123425T1 (el) 2021-12-31
FIC20230016I1 (fi) 2023-04-26
RS60387B1 (sr) 2020-07-31
US20190106482A1 (en) 2019-04-11
EP3094353B1 (en) 2020-04-01
BR112016015044A2 (pt) 2017-09-19
SMT202000282T1 (it) 2020-07-08
JP2017504321A (ja) 2017-02-09
JP2020103293A (ja) 2020-07-09
HRP20200607T1 (hr) 2020-07-10
ES2795727T9 (en) 2026-01-21
PL3094353T3 (pl) 2020-09-07
BR112016015044A8 (pt) 2023-04-11
HUE048855T2 (hu) 2020-08-28
AU2025201056A1 (en) 2025-03-06
JP2023052693A (ja) 2023-04-11
NL301228I1 (https=) 2023-05-03
LT3094353T (lt) 2020-08-10
HUS2300019I1 (hu) 2023-05-28
EP4353316A2 (en) 2024-04-17
WO2015108967A2 (en) 2015-07-23
AU2021204339A1 (en) 2021-07-22
WO2015108967A8 (en) 2015-10-01
MX2016008639A (es) 2017-02-15
TW201612191A (en) 2016-04-01
RU2016133247A3 (https=) 2019-01-16
SI3094353T1 (sl) 2020-07-31
DK3094353T3 (da) 2020-06-02
EP4353316A3 (en) 2024-08-21
JP6836398B2 (ja) 2021-03-03
LTC3094353I2 (https=) 2025-07-10
US11186628B2 (en) 2021-11-30
NL301228I2 (nl) 2023-09-13
CN105916520A (zh) 2016-08-31
RU2016133247A (ru) 2018-02-20
KR102188437B1 (ko) 2020-12-08
LTPA2023514I1 (https=) 2023-05-25
KR20160104018A (ko) 2016-09-02
US20230365660A1 (en) 2023-11-16
US10689437B2 (en) 2020-06-23
US20200331989A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
US12173050B2 (en) RSV-specific antibodies and functional parts thereof
WO2021245184A1 (en) HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
JP2024522670A (ja) 呼吸器合胞体ウイルスに対する抗体及びその使用
JP6538151B2 (ja) 抗ｃ型肝炎抗体及びその抗原結合断片
RU2785598C2 (ru) Rsv-специфичные антитела и их функциональные части
HK40109087A (en) Rsv-specific antibodies and functional parts thereof
HK40041855A (en) Rsv-specific antibodies and functional parts thereof
EP4729536A1 (en) Hepatitis b virus surface antibody and use thereof
HK1225992B (en) Rsv-specific antibodies and functional parts thereof
BR112016015044B1 (pt) Anticorpos específicos para rsv e partes funcionais dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination